During the last session, Generation Bio Co. (NASDAQ:GBIO)’s traded shares were 0.31 million. At the end of the trading day, the stock’s price was $6.00, reflecting an intraday gain of 4.35% or $0.25. The 52-week high for the GBIO share is $35.40, that puts it down -490.0 from that peak though still a striking 34.0% gain since the share price plummeted to a 52-week low of $3.96. The company’s market capitalization is $387.60M, and the average intraday trading volume over the past 10 days was 0.48 million shares, and the average trade volume was 450.49K shares over the past three months.
Generation Bio Co. (GBIO) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.00. GBIO has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.57.
Generation Bio Co. (NASDAQ:GBIO) trade information
Generation Bio Co. (GBIO) registered a 4.35% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.35% in intraday trading to $6.00 this Friday, 05/13/22, hitting a weekly high. The stock’s 5-day price performance is 5.45%, and it has moved by -35.21% in 30 days. Based on these gigs, the overall price performance for the year is -81.10%. The short interest in Generation Bio Co. (NASDAQ:GBIO) is 5.64 million shares and it means that shorts have 9.62 day(s) to cover.
The consensus price target of analysts on Wall Street is $20.00, which implies an increase of 70.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $10.00 and $29.00 respectively. As a result, GBIO is trading at a discount of -383.33% off the target high and -66.67% off the low.
Generation Bio Co. (GBIO) estimates and forecasts
Statistics show that Generation Bio Co. has underperformed its competitors in share price, compared to the industry in which it operates. Generation Bio Co. (GBIO) shares have gone down -71.66% during the last six months, with a year-to-date growth rate less than the industry average at -21.23% against 6.80. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -111.10% this quarter and then drop -21.70% in the quarter after that.
Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to $1.5 million by the end of Mar 2022.
While earnings are projected to return -21.70% in 2022.
Generation Bio Co. is due to release its next quarterly earnings between March 16 and March 21. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Generation Bio Co. (NASDAQ:GBIO)’s Major holders
Generation Bio Co. insiders own 8.65% of total outstanding shares while institutional holders control 99.00%, with the float percentage being 108.37%. Price (T.Rowe) Associates Inc is the largest shareholder of the company, while 153 institutions own stock in it. As of Sep 29, 2021, the company held over 8.63 million shares (or 15.16% of all shares), a total value of $216.31 million in shares.
The next largest institutional holding, with 8.52 million shares, is of FMR, LLC’s that is approximately 14.97% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $213.52 million.
Also, the Mutual Funds coming in first place with the largest holdings of Generation Bio Co. (GBIO) shares are Price (T.Rowe) New Horizons Fund and Fidelity Growth Company Fund. Data provided on Sep 29, 2021 indicates that Price (T.Rowe) New Horizons Fund owns about 2.61 million shares. This amounts to just over 4.58 percent of the company’s overall shares, with a $65.38 million market value. The same data shows that the other fund manager holds slightly less at 2.4 million, or about 4.21% of the stock, which is worth about $50.27 million.